TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05783401

Intervention type: DIAGNOSTIC_TEST
Intervention: Data acquisition: G8 Screening tool
Description: The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.

Intervention type: DIAGNOSTIC_TEST
Intervention: Data acquisition: Distress Thermometer
Description: The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Data acquisition: Distress Thermometer
Description: The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.
Study: NCT05859464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1218
Description: ZL-1218 dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1218
Description: ZL-1218 dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1218
Description: ZL-1218 dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1218
Description: ZL-1218 dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Combination treatment with ZL-1218
Study: NCT04239235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRAFT
Description: CRAFT is an evidence-based and non-confrontational approach for teaching friends/family members strategies to help their loved one reduce/refrain from using substances. It focuses on improving the lives of both the friends/family members and the individual struggling with substance use.
Study: NCT05859464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Combination treatment with ZL-1218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Combination treatment with ZL-1218
Study: NCT05956145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
Study: NCT06781541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic walking
Description: NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
Study: NCT04641975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
Study: NCT06781541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bungy Pump Exercises
Description: Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, a total of 12 weeks. Participants used professional Bungy Pump Pole.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily life
Description: The individuals engaged in routine daily tasks, while being advised against incorporating any supplementary physical exertion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional general conditioning training
Description: Training sessions were supervised by a certified instructor. Training was carried out at home with individually adjusted resistance depending on age and health. Participants typically performed 10-13 repetitions of a given exercise. 30-second rest intervals were used between exercises. As intended, the training was comprehensive, i.e. including muscles of the arms, legs, trunk, abdomen, chest, balance and flexibility exercises. Basic training equipment was used during the training.
Study: NCT06780527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15% Grape seed extract as dentin pretreatment
Description: using proanthocyanidin-rich grape seed extract as a biomodifier for dentin improved the mechanical properties of dental collagen by cross-linking and dehydrating fibrils. This made the collagen substrate more suitable for hybridization. It also acted as a non-specific MMP-inhibitor, protecting exposed collagen fibrils from biodegradation from dentin proteases.
Study: NCT06780176

Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Blood collection at baseline and time of surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Surgical Tissue Collection
Description: Tissue collection will be attempted at time of surgery

Intervention type: BEHAVIORAL
Intervention: Survey Collection
Description: Survey collection at baseline, post-surgery, at 1, 3 and 5 year follow up visits
Study: NCT06780319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: rehabilitation with a private physiotherapist. Patients usually undergo 15 rehabilitation sessions, in line with HAS recommendations; the number of sessions can go up to 25, depending on the patient's profile and needs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation
Description: Tele-education is a digital home-based intervention involving exercises and education. Patients are monitored remotely by a physiotherapist via a secure messaging system. The system consists of a mobile application for the patient and a web portal enabling the physiotherapist to review patient data (physical activity, pain levels, medication use, exercise adherence, patient-reported results, images, videos) on a daily basis and tailor the protocol accordingly.
Study: NCT06781216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: It is emphasized that motivational interviewing is a feasible intervention that can be used by various health professionals to optimize clinical outcomes in cancer patients and survivors, helping individuals to better cope with the stress they experience related to cancer and improve their quality of life. Considering the benefits of motivational interviewing on individuals diagnosed with cancer, it is anticipated that the intervention planned in the study will improve coping strategies, reduce post-traumatic stress symptoms, and increase the level of post-traumatic growth in women with endometrial cancer.
Study: NCT06782334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-116
Description: AMT-116 is an antibody Drug Conjugate (ADC)

Intervention type: DRUG
Group type: OTHER
Intervention: AMT-116
Description: AMT-116 is an antibody Drug Conjugate (ADC)
Study: NCT06781658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured rehabilitation intervention
Description: Participants will be prescribed a multi-component SRI which will include education, cervical range of motion exercises, progressive neck strengthening exercises, individualised scapular and upper limb strengthening, task specific hand function training and a physical activity behavioural change intervention. The TIDieR checklist has been used to provide a comprehensive description of this complex intervention. (17).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Surveillance
Description: Participants assigned to the clinical surveillance control group will be invited to attend a single, one to one education session which will be supplemented with a written patient information booklet after which they will be scheduled for a 12 week follow up.
Study: NCT06373380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-200
Description: HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every 3 weeks intravenously for 5 doses and then every 6 weeks thereafter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo arm will be receiving vehicle on the same schedule. Patients will receive treatment with HB-200 alternating therapy or placebo until recurrence or for a total duration of 1 year.
Study: NCT05315167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRJ1-3024
Description: PRJ1-3024 is provided as capsules and is administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRJ1-3024
Description: PRJ1-3024 is provided as capsules and is administered orally once a day.
Study: NCT06448780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate 20 mg/kg
Description: Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate 30 mg/kg
Description: Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
Study: NCT05342636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
Study: NCT04641975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral/ Oral Suspension
Study: NCT05342636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coformulation favezelimab/pembrolizumab
Description: 800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: 800 mg administered via IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: 800 mg administered via IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg administered via oral capsules each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
Study: NCT04905290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left ventricular coronary sinus (BiV) configuration
Description: For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay. Patients with a defibrillator will receive two additional delays LV precedes default by 30ms and LV precedes default by 60ms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing-only configuration
Description: Conduction System Pacing (CSP) of the left bundle branch. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, and default - 60ms AV delay.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction System Pacing Optimized Therapy (CSPOT) configuration
Description: A combination of Left Ventricle pacing and Conduction System Pacing of the left bundle branch. During the acute protocol, the eight delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay, CSP precedes default by 30ms, LV precedes default by 30ms and LV precedes default by 60ms.
Study: NCT06332482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant supported screw retained prosthesis
Description: All patients will receive six maxillary and mandibular implants for full arch screw retained prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant supported screw retained prosthesis
Description: All patients will receive six maxillary and mandibular implants for full arch screw retained prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant supported screw retained prosthesis
Description: All patients will receive six maxillary and mandibular implants for full arch screw retained prosthesis
Study: NCT05822817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Anesthesia is maintained with inhalation of sevoflurane. The concentration of sevoflurane was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Anesthesia is maintained with an effect-site target-controlled infusion of propofol (2-6ug/ml) based on the Marsh mode. The concentration of propofol was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
Study: NCT04641975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral/ Oral Suspension
Study: NCT06552169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: SOC (mTOR + CNI)
Description: Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm 2A: TRACT/MONO mTOR
Description: All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product.
Study: NCT06483217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-directed follow up
Description: Patients will be instructed to follow up for repeat injection based on bladder symptomatology at their own self-determined time interval.
Study: NCT06361446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 50 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT06552169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm 2B: TRACT/MONO CNI
Description: All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product.
Study: NCT05121038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEND-1
Description: The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEND-1
Description: The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEND-1
Description: The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX.
Study: NCT06008171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Decision Aid
Description: A designed tool (by us) that help patients and providers talk and decide together about field-directed treatment options for actinic keratosis.
Study: NCT05121038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.
Study: NCT05354284

Intervention type: OTHER
Intervention: online questionnaire
Description: Questionnaire at three timepoints